AU2001232267A1 - Remedies for hepatitis c - Google Patents

Remedies for hepatitis c

Info

Publication number
AU2001232267A1
AU2001232267A1 AU2001232267A AU3226701A AU2001232267A1 AU 2001232267 A1 AU2001232267 A1 AU 2001232267A1 AU 2001232267 A AU2001232267 A AU 2001232267A AU 3226701 A AU3226701 A AU 3226701A AU 2001232267 A1 AU2001232267 A1 AU 2001232267A1
Authority
AU
Australia
Prior art keywords
hepatitis
remedies
virus
present
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232267A
Inventor
Seima Itami
Yoshiharu Matsuura
Tatsuo Miyamura
Makoto Seki
Tatsurou Shibui
Yoshihisa Yotsumoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JAPAN AS REPRESENTED BY DIRECTOR GENERAL OF AGENCY OF NATIONAL INSTITUTE OF INFECTIOUS DESEASES
Mitsubishi Tokyo Pharmaceuticals Inc
Original Assignee
JP AGENCY OF NAT
Mitsubishi Tokyo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JP AGENCY OF NAT, Mitsubishi Tokyo Pharmaceuticals Inc filed Critical JP AGENCY OF NAT
Publication of AU2001232267A1 publication Critical patent/AU2001232267A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81. The present invention can provide a novel medicament which has an anti-viral effects such as an inhibitory action against HCV infection.
AU2001232267A 2000-02-14 2001-02-13 Remedies for hepatitis c Abandoned AU2001232267A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-34906 2000-02-14
JP2000034906 2000-02-14
PCT/JP2001/000967 WO2001058459A1 (en) 2000-02-14 2001-02-13 Remedies for hepatitis c

Publications (1)

Publication Number Publication Date
AU2001232267A1 true AU2001232267A1 (en) 2001-08-20

Family

ID=18559171

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232267A Abandoned AU2001232267A1 (en) 2000-02-14 2001-02-13 Remedies for hepatitis c

Country Status (8)

Country Link
US (1) US7101551B2 (en)
EP (1) EP1256348B1 (en)
KR (1) KR20020091093A (en)
CN (1) CN100391469C (en)
AT (1) ATE555794T1 (en)
AU (1) AU2001232267A1 (en)
BR (1) BR0108499A (en)
WO (1) WO2001058459A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047392A1 (en) * 2002-10-22 2006-01-18 Wyeth Corp NEUTRALIZATION OF ANTIBODIES AGAINST GDF 8 AND ITS USE FOR SUCH PURPOSES
EP1662007B9 (en) * 2003-08-28 2012-02-29 Dainippon Sumitomo Pharma Co., Ltd. Preventive or remedy for inflammatory bowel diseases containing anti-cd81 antibody as the active ingredient
US7750115B2 (en) * 2004-03-31 2010-07-06 Patent Technology Development, Inc. Epithelial cell growth promoter
UA94403C2 (en) 2005-04-18 2011-05-10 Микромет Аг Human monoclonal antibody neutralizing granulocyte macrophage colony stimulating factor
US9296810B2 (en) * 2008-05-02 2016-03-29 Novartis Ag Fibronectin-based binding molecules and uses thereof
EP3434769B1 (en) 2009-10-30 2020-11-25 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
EP2575885A1 (en) 2010-05-25 2013-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
CA2820134A1 (en) * 2010-12-06 2012-06-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024157A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of host targeting agents for the treatment and the prevention of hcv infection
WO2013024155A1 (en) 2011-08-17 2013-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations of anti-hcv-entry factor antibodies and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
AR093297A1 (en) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
EP3889178A1 (en) 2013-08-30 2021-10-06 Takeda GmbH Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
CN107106665A (en) 2014-06-06 2017-08-29 纪念斯隆-凯特琳癌症中心 Target Chimeric antigen receptor of mesothelin and application thereof
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
SG11202100373VA (en) 2018-07-20 2021-02-25 Surface Oncology Inc Anti-cd112r compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
JPH08510240A (en) * 1993-05-12 1996-10-29 カイロン コーポレイション Conserved motif of hepatitis C virus E2 / NS1 region
CN1044384C (en) * 1994-08-25 1999-07-28 中国药品生物制品检定所 Building of anti-type-C hepatitis virus antigen monoclonal antibody cell strain and monoclonal antibody thereof
CN1072482C (en) * 1996-11-08 2001-10-10 山东医科大学 Low-molecular heparin liposome spray preparation and its preparation
ES2334727T3 (en) * 1997-10-06 2010-03-15 Novartis Vaccines And Diagnostics S.R.L. RECEIVING PROTEIN CD81 OF HEPATITIS C.
JP4593783B2 (en) * 1998-07-21 2010-12-08 ゲンマブ・アクティーゼルスカブ Anti-hepatitis C virus antibody and use thereof
WO2000026418A1 (en) 1998-11-05 2000-05-11 The Board Of Trustees Of Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
EP1293564A4 (en) 2000-06-08 2005-08-17 Mitsubishi Pharma Corp Expression vector enabling screening of cells with high expression of recombinant protein, transformant with high expression of recombinant protein and utilization thereof

Also Published As

Publication number Publication date
EP1256348A1 (en) 2002-11-13
ATE555794T1 (en) 2012-05-15
EP1256348B1 (en) 2012-05-02
US20030157132A1 (en) 2003-08-21
CN1423561A (en) 2003-06-11
WO2001058459A1 (en) 2001-08-16
EP1256348A4 (en) 2005-07-27
BR0108499A (en) 2003-03-11
KR20020091093A (en) 2002-12-05
CN100391469C (en) 2008-06-04
US7101551B2 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
AU2001232267A1 (en) Remedies for hepatitis c
WO2004011478A3 (en) Anti-viral 7-deaza d-nucleosides and uses thereof
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
WO2003053349A3 (en) Inhibitors of hepatitis c virus
WO2007084413A3 (en) Methods for treating hepatitis c
PT1169339E (en) ACTIVE MACROCYCLIC PEPTIDES AGAINST HEPATITIS C VIRUSES
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
MXPA02012443A (en) 3 -PRODRUGS OF 2 -DEOXY-bgr;-L-NUCLEOSIDES.
DE50102597D1 (en) MEDICINE AGAINST VIRAL DISEASES
ID27457A (en) COMPOSITION FOR HIV TREATMENT AND OTHER VIRUS INFECTIONS
NO20051969L (en) Nucleoside derivatives for the treatment of hepatitis C virus infection.
UA85536C2 (en) Viral antigens
WO2010047830A3 (en) Agents for hcv treatment
AU2002343556A1 (en) Use of phosphonate nucleotide analogue for treating hepatitis b virus infections
DK1037650T3 (en) Preparations for the treatment of Staphylococcus aureus infections
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
WO2002062959A3 (en) Hepatitis b virus treatment
ATE299709T1 (en) ANTI-VIRAL COMPOSITION CONTAINING A PALMARIA PALMATA EXTRACT
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
WO2003053332A3 (en) Composition and method for treating viral infection
AU2002322082A1 (en) Pharmaceutical composition for the treatment of viral infection
WO2006019841A3 (en) Treatment of viral infections with egr 1 activators